Evidence map›Paper›PMID 29661994›Full record

ArticleJournal of clinical medicine2018

Baseline Apparent Diffusion Coefficient as a Predictor of Response to Liver-Directed Therapies in Hepatocellular Carcinoma.

Andrew Niekamp, Reham Abdel-Wahab, Joshua Kuban, Bruno C Odisio, Armeen Mahvash, Manal M Hassan, Aliya Qayyum, Ahmed Kaseb, Rahul A Sheth

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Empirical validation of gradient field models for an accurate ADC measured on clinical 3T MR systems in body oncologic applications.Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics (AIFB) · 2021
    Article
  4. Article
  5. Prediction of hepatocellular carcinoma response toCancer imaging : the official publication of the International Cancer Imaging Society · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Andrew NiekampDepartment of Interventional Radiology, Division of Diagnostic Imaging, MD Anderson Cancer Center, Houston, TX 77030, USA. Andrew.S.Niekamp@uth.tmc.edu.
Reham Abdel-WahabDepartment of Gastrointestinal Medical Oncology, MD Anderson Cancer Center, Houston, TX 77030, USA.
Joshua KubanDepartment of Interventional Radiology, Division of Diagnostic Imaging, MD Anderson Cancer Center, Houston, TX 77030, USA. jdkuban@mdanderson.org.
Bruno C OdisioDepartment of Interventional Radiology, Division of Diagnostic Imaging, MD Anderson Cancer Center, Houston, TX 77030, USA. BCOdisio@mdanderson.org.
Armeen MahvashDepartment of Interventional Radiology, Division of Diagnostic Imaging, MD Anderson Cancer Center, Houston, TX 77030, USA. armeen.mahvash@mdanderson.org.
Manal M HassanDepartment of Gastrointestinal Medical Oncology, MD Anderson Cancer Center, Houston, TX 77030, USA. mhassan@mdanderson.org.
Aliya QayyumDivision of Diagnostic Imaging, MD Anderson Cancer Center, Houston, TX 77030, USA. AQayyum@mdanderson.org.
Ahmed KasebDepartment of Gastrointestinal Medical Oncology, MD Anderson Cancer Center, Houston, TX 77030, USA. akaseb@mdanderson.org.
Rahul A ShethDepartment of Interventional Radiology, Division of Diagnostic Imaging, MD Anderson Cancer Center, Houston, TX 77030, USA. rasheth@mdanderson.org.
The University of Texas MD Anderson Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Predicting outcomes in patients with hepatocellular carcinoma (HCC) who undergo locoregional therapies remains a substantial clinical challenge. The purpose of this study was to investigate pre-procedure diffusion weighted magnetic resonance imaging (DW-MRI) as an imaging biomarker for tumoral response to therapy for patients with HCC undergoing drug eluting embolic (DEE) chemoembolization and radioembolization. A retrospective review of HCC patients who underwent DEE chemoembolization or radioembolization was performed. Of the 58 patients who comprised the study population, 32 underwent DEE chemoembolization and 26 underwent radioembolization. There was no significant difference in median apparent diffusion coefficient (ADC) values across the two treatment groups (1.01 × 10

Indexed as

chemoembolizationdiffusion weighted imaginghepatocellular carcinoma

Identifiers

PMID29661994
PMCPMC5920457
OpenAlexW2797512767

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.